Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids.

BACKGROUND There is growing evidence about illicit use of buprenorphine in the U.S. The study aims to: (1) identify prevalence and predictors of illicit buprenorphine use in a community sample of 396 young adult (18-23 years old) non-medical users of pharmaceutical opioids and (2) describe knowledge, attitudes and behaviors linked to illicit buprenorphine use as reported by a qualitative sub-sample (n=51). METHODS Participants were recruited using respondent-driven sampling. Qualitative interview participants were selected from the larger sample. The sample (n=396) was 54% male and 50% white; 7.8% reported lifetime illicit use of buprenorphine. RESULTS Logistic regression analysis results indicate that white ethnicity, intranasal inhalation of pharmaceutical opioids, symptoms of opioid dependence, and a greater number of pharmaceutical opioids used in lifetime were statistically significant predictors of illicit buprenorphine use. Qualitative interviews revealed that buprenorphine was more commonly used by more experienced users who were introduced to it by their "junkie friends." Those who used buprenorphine to self-medicate withdrawal referred to it as a "miracle pill." When used to get high, reported experiences ranged from "the best high ever" to "puking for days." Participants reported using buprenorphine/naloxone orally or by intranasal inhalation. Injection of buprenorphine without naloxone was also reported. CONCLUSION Our findings suggest that illicit buprenorphine use is gaining ground primarily among whites and those who are more advanced in their drug use careers. Continued monitoring is needed to better understand evolving patterns and trends of illicit buprenorphine use.

[1]  C. Schuster,et al.  Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. , 2012, Drug and alcohol dependence.

[2]  C. Teddlie,et al.  SAGE Handbook of Mixed Methods in Social & Behavioral Research , 2010 .

[3]  R. Carlson.  'Boy' and 'Girl': The AIDS Risk Implications of Heroin and Cocaine Symbolism Among Injection Drug Users , 1999 .

[4]  C. Turner,et al.  Assessing consistency of responses to questions on cocaine use. , 1995, Addiction.

[5]  Jeffrey J. Annon,et al.  A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. , 2005, Addiction.

[6]  J. Rich,et al.  Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. , 2011, Current drug abuse reviews.

[7]  M. Stitzer,et al.  A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. , 1995, Drug and alcohol dependence.

[8]  S. Walsh,et al.  Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. , 2011, Journal of substance abuse treatment.

[9]  John W. Creswell,et al.  Designing A Mixed Methods Study In Primary Care , 2004, The Annals of Family Medicine.

[10]  D. Leiderman,et al.  Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. , 2003, Drug and alcohol dependence.

[11]  R. D. Bruce,et al.  Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia , 2008, The American journal of drug and alcohol abuse.

[12]  R. Carlson,et al.  Respondent-driven sampling to recruit young adult non-medical users of pharmaceutical opioids: problems and solutions. , 2012, Drug and alcohol dependence.

[13]  M. Stitzer,et al.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. , 2000, The New England journal of medicine.

[14]  M. Agar,et al.  Buprenorphine: “Field Trials” of a New Drug , 2001, Qualitative health research.

[15]  Douglas D. Heckathorn,et al.  Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hi , 2002 .

[16]  R. Turner,et al.  Early and mid-adolescence risk factors for later substance abuse by African Americans and European Americans. , 2002, Public health reports.

[17]  A. Chowdhury,et al.  Buprenorphine abuse: report from India. , 1990, British journal of addiction.

[18]  Meredith Y. Smith,et al.  Correlates of Nonmedical Use of Hydromorphone and Hydrocodone , 2007, Journal of pain & palliative care pharmacotherapy.

[19]  L. Johnston,et al.  Tobacco, alcohol, and illicit drug use: racial and ethnic differences among U.S. high school seniors, 1976-2000. , 2002, Public health reports.

[20]  I. Varescon,et al.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. , 2003, Drug and alcohol dependence.

[21]  F. Schifano,et al.  Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002 , 2005, Human psychopharmacology.

[22]  S. Darke,et al.  Self-report among injecting drug users: a review. , 1998, Drug and alcohol dependence.

[23]  S. Shiffman,et al.  Non-Medical Use of OxyContin Tablets in the United States , 2005, Journal of pain & palliative care pharmacotherapy.

[24]  G. Woody,et al.  Abuse of Buprenorphine in the United States , 2007, Journal of addictive diseases.

[25]  A. Winstock,et al.  The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia. , 2011, The International journal on drug policy.

[26]  J. Maxwell,et al.  Indicators of buprenorphine and methadone use and abuse: what do we know? , 2010, The American journal on addictions.

[27]  N. Clark,et al.  Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? , 2005, Addiction.

[28]  S. Martins,et al.  Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population. , 2009, Drug and alcohol dependence.

[29]  Jeffrey J. Annon,et al.  Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. , 2004, The American journal on addictions.

[30]  P. Marquet,et al.  [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases--20 fatal cases]. , 1998, Presse medicale.

[31]  T. Parfitt.  Designer drug Subutex takes its toll in Tbilisi , 2006, The Lancet.

[32]  Matthew B. Miles,et al.  Qualitative Data Analysis: An Expanded Sourcebook , 1994 .

[33]  J. Rich,et al.  Illicit Use of Buprenorphine/Naloxone Among Injecting and Noninjecting Opioid Users , 2011, Journal of addiction medicine.

[34]  R. Turner,et al.  Psychiatric and substance use disorders in South Florida: racial/ethnic and gender contrasts in a young adult cohort. , 2002, Archives of general psychiatry.

[35]  H. Neighbors,et al.  Racial/Ethnic differences in smoking, drinking, and illicit drug use among American high school seniors, 1976-89. , 1991, American journal of public health.

[36]  Douglas D. Heckathorn,et al.  Respondent-driven sampling : A new approach to the study of hidden populations , 1997 .

[37]  A. Strauss,et al.  Basics of qualitative research: Grounded theory procedures and techniques. , 1992 .

[38]  B. Ludes,et al.  Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. , 1998, Journal of analytical toxicology.

[39]  M. Agar,et al.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. , 2009, The American journal on addictions.

[40]  Edward W Boyer,et al.  Diversion of Buprenorphine/Naloxone Coformulated Tablets in a Region with High Prescribing Prevalence , 2009, Journal of addictive diseases.

[41]  Sarah E. Nelson,et al.  Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. , 2010, Journal of substance abuse treatment.

[42]  J. Inciardi,et al.  Use and misuse of buprenorphine in the management of opioid addiction. , 2007, Journal of opioid management.

[43]  N. Dasgupta,et al.  OPIOIDS, SUBSTANCE ABUSE & ADDICTIONS SECTION Original Research Article Post-marketing Surveillance of Methadone and Buprenorphine in the United States , 2010 .

[44]  R. Carlson,et al.  Methamphetamine Use in Dayton, Ohio: Preliminary Findings from the Ohio Substance Abuse Monitoring Network , 2007, Journal of psychoactive drugs.

[45]  R. Carlson,et al.  Initiation to Pharmaceutical Opioids and Patterns of Misuse: Preliminary Qualitative Findings Obtained by the Ohio Substance Abuse Monitoring Network , 2006 .